Kedar B Joshi1, Anup Nillawar2, A P Thorat3. 1. Assistant Professor, Department of Biochemistry GMC Aurangabad, Maharashtra, India . 2. Associate Professor, Department of Biochemistry, SBKS Medical College , Vadodara, Gujarat, India . 3. Professor and Head, Department of Biochemistry, GMC Aurangabad Maharashtra, India .
Abstract
BACKGROUND: The Schizophrenia patients are at higher risk for cardiovascular morbidity and mortality. The aim of this case-control study is to measure Cardiovascular Disease (CVD) risk parameters in patient group and compare it with normal population. METHODOLOGY: We recruited 45 cases of Schizophrenia diagnosed by diagnostic and statistical manual of mental disorders (DSM-IV) criteria and 41 healthy controls from general population. The body mass index, metabolic syndrome parameters, lipid parameters and high sensitive C-reactive protein were measured in both groups. Metabolic syndrome and dyslipidemia prevalence were assessed based on National Cholesterol Education Programme (NCEP) Adult Treatment Panel III (ATP III) guidelines. RESULTS: The Schizophrenia subjects showed statistically significant high waist circumference, increased triglycerides and decreased HDL cholesterol values. The subjects also showed statistically significant increased hs-CRP values. The prevalence of metabolic syndrome and laboratory dyslipidemia were 28.8% and 51.1% respectively, which were higher compared to control group. CONCLUSION: The Schizophrenia subjects are at higher risk for cardiovascular disease events due to high prevalence of metabolic syndrome and dyslipidemia. These patients should be regularly monitored for CVD risk factors and timely referred to physician for further management.
BACKGROUND: The Schizophreniapatients are at higher risk for cardiovascular morbidity and mortality. The aim of this case-control study is to measure Cardiovascular Disease (CVD) risk parameters in patient group and compare it with normal population. METHODOLOGY: We recruited 45 cases of Schizophrenia diagnosed by diagnostic and statistical manual of mental disorders (DSM-IV) criteria and 41 healthy controls from general population. The body mass index, metabolic syndrome parameters, lipid parameters and high sensitive C-reactive protein were measured in both groups. Metabolic syndrome and dyslipidemia prevalence were assessed based on National Cholesterol Education Programme (NCEP) Adult Treatment Panel III (ATP III) guidelines. RESULTS: The Schizophrenia subjects showed statistically significant high waist circumference, increased triglycerides and decreased HDL cholesterol values. The subjects also showed statistically significant increased hs-CRP values. The prevalence of metabolic syndrome and laboratory dyslipidemia were 28.8% and 51.1% respectively, which were higher compared to control group. CONCLUSION: The Schizophrenia subjects are at higher risk for cardiovascular disease events due to high prevalence of metabolic syndrome and dyslipidemia. These patients should be regularly monitored for CVD risk factors and timely referred to physician for further management.
Authors: W Koenig; M Sund; M Fröhlich; H G Fischer; H Löwel; A Döring; W L Hutchinson; M B Pepys Journal: Circulation Date: 1999-01-19 Impact factor: 29.690
Authors: Shaista Malik; Nathan D Wong; Stanley Franklin; Jose Pio; Carol Fairchild; Roland Chen Journal: Diabetes Care Date: 2005-03 Impact factor: 19.112
Authors: Mas Ayu Said; Ahmad Hatim Sulaiman; Mohd Hussain Habil; Srijit Das; Abdul Kadir Abu Bakar; Rosliwati Md Yusoff; Tsui Huei Loo; Shamshunnisah Abu Bakar Journal: Singapore Med J Date: 2012-12 Impact factor: 1.858
Authors: Waleed M Sweileh; Sa'ed H Zyoud; Salah A Dalal; Sami Ibwini; Ansam F Sawalha; Iyad Ali Journal: BMC Psychiatry Date: 2012-12-27 Impact factor: 3.630
Authors: B S Fernandes; J Steiner; H-G Bernstein; S Dodd; J A Pasco; O M Dean; P Nardin; C-A Gonçalves; M Berk Journal: Mol Psychiatry Date: 2015-07-14 Impact factor: 15.992
Authors: Elina J Reponen; Ingrid Dieset; Martin Tesli; Ragni H Mørch; Monica Aas; Trude S J Vedal; Elisabeth Haug; Ole Kristian Drange; Nils Eiel Steen; Sigrun Hope; Attila Szabo; Sherif M Gohar; Kirsten Wedervang-Resell; Srdjan Djurovic; Ingrid Melle; Pål Aukrust; Ole A Andreassen; Thor Ueland Journal: Front Psychiatry Date: 2020-07-10 Impact factor: 4.157
Authors: Mª Carmen Castillejos; Carlos Martín-Pérez; Antonio García-Ruiz; Fermín Mayoral-Cleries; Berta Moreno-Küstner Journal: Ann Gen Psychiatry Date: 2020-05-19 Impact factor: 3.455